• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度普利尤单抗治疗高IgE综合征相关疾病:一例报告

Hyper IgE syndrome-related disease treated with dupilumab: A case report.

作者信息

Kao Andrew S, Deirawan Hany, Poowuttikul Pavadee, Daveluy Steven

机构信息

Department of Dermatology Wayne State University School of Medicine Dearborn Michigan USA.

Department of Pediatrics Division of Allergy, Immunology, and Rheumatology Central Michigan University Dearborn Michigan USA.

出版信息

Clin Case Rep. 2023 Sep 13;11(9):e7614. doi: 10.1002/ccr3.7614. eCollection 2023 Sep.

DOI:10.1002/ccr3.7614
PMID:37720709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10500051/
Abstract

Phosphoglucomutase 3 (PGM3) catalyzes the glycosylation of immune system precursor proteins. Its impairment leads to severe infections and other developmental, musculoskeletal, and nervous system defects. We present a case of a 2-month-old female patient with recurrent infections and diffuse eczematous dermatitis recalcitrant to corticosteroids. A next-generation sequencing NGS gene panel for inherited immune dysfunction syndromes revealed multiple variants of unknown significance in key immune regulators, specifically heterozygous mutation c.337C⟩G (p.Pro113Ala) on exon 4 of PGM3 as a novel variant in the PGM3 associated diseases. Off-label use of dupilumab resulted in rapid improvement.

摘要

磷酸葡萄糖变位酶3(PGM3)催化免疫系统前体蛋白的糖基化。其功能受损会导致严重感染以及其他发育、肌肉骨骼和神经系统缺陷。我们报告了一例2个月大的女性患者,该患者反复感染且患有对皮质类固醇耐药的弥漫性湿疹性皮炎。针对遗传性免疫功能障碍综合征的下一代测序(NGS)基因检测板显示关键免疫调节因子存在多个意义未明的变异,特别是PGM3第4外显子上的杂合突变c.337C⟩G(p.Pro113Ala),这是PGM3相关疾病中的一种新变异。度普利尤单抗的超说明书使用带来了快速改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6751/10500051/d9da061debb6/CCR3-11-e7614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6751/10500051/a4cd12db763e/CCR3-11-e7614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6751/10500051/d9da061debb6/CCR3-11-e7614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6751/10500051/a4cd12db763e/CCR3-11-e7614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6751/10500051/d9da061debb6/CCR3-11-e7614-g001.jpg

相似文献

1
Hyper IgE syndrome-related disease treated with dupilumab: A case report.度普利尤单抗治疗高IgE综合征相关疾病:一例报告
Clin Case Rep. 2023 Sep 13;11(9):e7614. doi: 10.1002/ccr3.7614. eCollection 2023 Sep.
2
Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.磷酸葡萄糖变位酶3(PGM3)的低表达纯合突变会损害免疫力并提高血清IgE水平。
J Allergy Clin Immunol. 2014 May;133(5):1410-9, 1419.e1-13. doi: 10.1016/j.jaci.2014.02.025. Epub 2014 Apr 1.
3
Novel PGM3 compound heterozygous variants with IgE-related dermatitis, lymphopenia, without syndromic features.新型 PGM3 复合杂合变异与 IgE 相关皮炎、淋巴细胞减少症,无综合征特征。
Pediatr Allergy Immunol. 2021 Apr;32(3):566-575. doi: 10.1111/pai.13398. Epub 2020 Nov 6.
4
Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene.1976年报道的无高免疫球蛋白E伴随的感染易感性,是由磷酸葡萄糖变位酶3(PGM3)基因的次等位基因突变引起的。
Clin Immunol. 2015 Dec;161(2):366-72. doi: 10.1016/j.clim.2015.10.002. Epub 2015 Oct 19.
5
Hyper-IgE syndromes: reviewing PGM3 deficiency.高免疫球蛋白E综合征:PGM3缺陷综述
Curr Opin Pediatr. 2014 Dec;26(6):697-703. doi: 10.1097/MOP.0000000000000158.
6
Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.度普利尤单抗清除高免疫球蛋白 E 综合征的非典型皮肤表现。
Pediatr Dermatol. 2022 Nov;39(6):940-942. doi: 10.1111/pde.15072. Epub 2022 Jun 22.
7
Two Novel Homozygous Mutations in Phosphoglucomutase 3 Leading to Severe Combined Immunodeficiency, Skeletal Dysplasia, and Malformations.两种新型磷酸葡萄糖变位酶 3 纯合突变导致严重联合免疫缺陷、骨骼发育不良和畸形。
J Clin Immunol. 2021 Jul;41(5):958-966. doi: 10.1007/s10875-021-00985-w. Epub 2021 Feb 3.
8
Glycoproteomic studies of IgE from a novel hyper IgE syndrome linked to PGM3 mutation.对一种与PGM3突变相关的新型高IgE综合征患者的IgE进行糖蛋白质组学研究。
Glycoconj J. 2016 Jun;33(3):447-56. doi: 10.1007/s10719-015-9638-y. Epub 2015 Dec 19.
9
Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment.常染色体隐性磷酸葡萄糖变位酶3(PGM3)突变将糖基化缺陷与特应性、免疫缺陷、自身免疫和神经认知障碍联系起来。
J Allergy Clin Immunol. 2014 May;133(5):1400-9, 1409.e1-5. doi: 10.1016/j.jaci.2014.02.013. Epub 2014 Feb 28.
10
Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report.严重免疫缺陷患者中 PGM3 有 11%完整,伴有新型剪接位点突变:病例报告。
BMC Pediatr. 2018 Aug 29;18(1):285. doi: 10.1186/s12887-018-1258-9.

引用本文的文献

1
Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper-IgE Syndrome: A Case Series and Literature Review.度普利尤单抗治疗不同遗传类型高IgE综合征儿童特应性皮炎及反复感染的疗效:病例系列及文献综述
Pediatr Dermatol. 2025 Mar-Apr;42(2):376-382. doi: 10.1111/pde.15780. Epub 2024 Oct 18.

本文引用的文献

1
Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.度普利尤单抗清除高免疫球蛋白 E 综合征的非典型皮肤表现。
Pediatr Dermatol. 2022 Nov;39(6):940-942. doi: 10.1111/pde.15072. Epub 2022 Jun 22.
2
Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.缓解性工作:度普利尤单抗治疗常染色体显性 STAT3 高 IgE 综合征
J Allergy Clin Immunol Pract. 2022 Jan;10(1):349-351.e1. doi: 10.1016/j.jaip.2021.08.042. Epub 2021 Sep 16.
3
Heterozygous Variants Are Associated With Idiopathic Focal Epilepsy With Incomplete Penetrance.
杂合变异与不完全外显的特发性局灶性癫痫相关。
Front Genet. 2020 Oct 15;11:559080. doi: 10.3389/fgene.2020.559080. eCollection 2020.
4
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.一项 2 期、开放标签研究,评估单剂量度普利尤单抗在 6 个月至<6 岁患有严重未控制特应性皮炎儿童中的药代动力学、安全性和疗效。
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475. doi: 10.1111/jdv.16928. Epub 2020 Nov 8.
5
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据:一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
6
Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.度普利尤单抗治疗高IgE综合征患者严重特应性皮炎的疗效
J Clin Immunol. 2020 Feb;40(2):418-420. doi: 10.1007/s10875-020-00751-4. Epub 2020 Jan 28.
7
Compound Heterozygous PGM3 Mutations in a Thai Patient with a Specific Antibody Deficiency Requiring Monthly IVIG Infusions.一名需要每月静脉注射免疫球蛋白(IVIG)的泰国特定抗体缺陷患者的复合杂合PGM3突变
J Clin Immunol. 2020 Jan;40(1):227-231. doi: 10.1007/s10875-019-00693-6. Epub 2019 Nov 9.
8
Selective loss of function variants in cause Hyper-IgE syndrome with distinct impairments of T-cell phenotype and function.在 中选择性丧失功能的变异导致高免疫球蛋白 E 综合征,表现为 T 细胞表型和功能的明显损伤。
Haematologica. 2019 Mar;104(3):609-621. doi: 10.3324/haematol.2018.194233. Epub 2018 Oct 11.
9
Hyper-IgE in the allergy clinic--when is it primary immunodeficiency?在过敏诊所中的高 IgE 血症——何时是原发性免疫缺陷?
Allergy. 2018 Nov;73(11):2122-2136. doi: 10.1111/all.13578. Epub 2018 Oct 2.
10
A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity.一种由 ZNF341 依赖性 STAT3 转录和活性破坏引起的高 IgE 综合征的隐性形式。
Sci Immunol. 2018 Jun 15;3(24). doi: 10.1126/sciimmunol.aat4956.